BioWorld

Sep. 23, 2003

BioMarin Stops Development Of Neutralase In CABG Surgery

Officials at BioMarin Inc. believe themselves to be fortunate in determining fairly early that their lead product, Neutralase, probably won't make it to market. (BioWorld Today) Read More

Pain Therapeutics Raises $49.7M In Follow-On; Neose Getting $23M

Controversy Smolders As To U.S. Regions Of Lyme Disease, Borrelia burgdorferi, Despite M.D. Practices

First-Round Financing Of $12.5M Puts Ambrx On Development Path

Genzyme Invests $37.7M In CAT As Companies Restructure Pact

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...